Skip to main content
SpringerLink
Log in

Pulmonale Manifestationen rheumatologischer Erkrankungen

  • Chapter
  • First Online:
Seltene Lungenerkrankungen

  • 2054 Accesses

Zusammenfassung

Kollagenosen und die rheumatoide Arthritis können mit verschiedenen pulmonalen und thorakalen Manifestationen assoziiert sein. Kollagenosen und Rheumatoide-Arthritis-assoziierte interstitielle Lungenerkrankungen (CTD-ILD) sind wichtige Differenzialdiagnosen interstitieller Lungenerkrankungen und häufig mit einer schlechten Prognose assoziiert. Die Abgrenzung zu infektiösen Komplikationen oder zur medikamentenassoziierten ILD ist zum Teil komplex. Eine Indikation zur immunsuppressiven Therapie bei CTD-ILD sollte interdisziplinär erfolgen; neben der immunmodulatorischen Therapie ist bei der Systemischen-Sklerodermie-ILD oder bei einer progredienten Fibrosierung auch eine antifibrotische Therapie zu bedenken . Eine weitere wichtige Organmanifestation ist die Kollagenose-assoziierte pulmonale Hypertonie. Daneben kann es auch zu Bronchiektasen/Bronchiolitiden, pleuralen Affektionen oder zu einer Mitbeteiligung der Atemmuskulatur kommen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Altmann RD, Medsger TA Jr, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis. Arthritis Rheum 34:403–413

    Article  Google Scholar 

  • Andersson H, Sem M, Lund MB, Aaløkken TM, Günther A, Walle-Hansen R, Garen T, Molberg Ø (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 54(8):1420–1428

    Article  CAS  Google Scholar 

  • Avouac J, Huscher D, Furst DE et al (2014) Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. Ann Rheum Dis 73(1):191–197

    Article  PubMed  Google Scholar 

  • Behr J, Günther A, Bonella F, Dinkel J, Fink L, Geiser T, Geißler K, Gläser S, Handzhhiev S, Jonigk D, Koschel D, Kreuter M, Leuschner G, Markart P, Prasse A, Schönfeld N, Schupp JC, Sitter H, Müller-Quernheim J, Costabel U (2020) German guideline for idiopathic pulmonary fibrosis. Pneumologie 74(5):e1–e2

    Article  CAS  PubMed  Google Scholar 

  • Behr et al (2021) A double-blind, randomised, placebo-controlled phase 2b trial exploring safety and efficacy of oral pirfenidone in progressive, non-IPF lung fibrosis (RELIEF-Study). Lancet Respir Med 9(5):476, im Druck

    Article  CAS  PubMed  Google Scholar 

  • Bouros D, Wells AU, Nicholson AG et al (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165:1581–1586

    Article  PubMed  Google Scholar 

  • Burt RK, Shah SJ, Dill K et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis: an open-label, randomised phase 2 trial. Lancet 378:498–506

    Article  CAS  PubMed  Google Scholar 

  • Cervera R, Khamashta MA, Font J et al (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78:167–175

    Article  CAS  Google Scholar 

  • Christian RB, Wells AU, Capelozzi VL, Silver RM (2010) Gastroesophagela reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 40:21–249

    Google Scholar 

  • Coghlan JG, Denton CP, Grünig E et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349. (DETECT Study Group)

    Article  PubMed  Google Scholar 

  • Cottin V (2013) Significance of connective tissue diseases features in pulmonary fibrosis. Eur Respir Rev 22:273–280

    Article  PubMed  Google Scholar 

  • Dekan G (2003) Histologische Klassifikation interstitieller Lungenerkrankungen. Z Rheumatol 62:16–20

    Article  PubMed  PubMed Central  Google Scholar 

  • Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, SENSCIS Trial Investigators (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380(26):2518–2528

    Article  CAS  PubMed  Google Scholar 

  • Fernández-Díaz C, Loricera J, Castañeda S et al (2018) Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum 48:22–27. https://doi.org/10.1016/j.semarthrit.2017.12.012

    Article  CAS  PubMed  Google Scholar 

  • Fischer A, Brown KK, Du Bois RM et al (2013) Mycophenolatemofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40(5):640–646

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fischer A, Antoniou KM, Brown KK et al (2015) An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46:976–987. https://doi.org/10.1183/13993003.00150-2015

    Article  CAS  PubMed  Google Scholar 

  • Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK, INBUILD Trial Investigators (2019) Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381(18):1718–1727

    Article  CAS  PubMed  Google Scholar 

  • Highland KB, Garin MC, Brown KK (2007) The spectrum of scleroderma lung disease. Semin Respir Crit Care Med 28:418–429

    Article  PubMed  Google Scholar 

  • Hoffmann-Vold A-M, Maher TM, Philpot EE et al (2020a) The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2:e71–e83

    Article  Google Scholar 

  • Hoffmann-Vold A-M, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, Bruni C, Carducci P, Carreira PE, Castellví I, Del Galdo F, Distler JH, Foeldvari I, Fraticelli P, George PM, Griffiths B, Guillén-Del-Castillo A, Hamid AM, Horváth R, Hughes M, Kreuter M, Moazedi-Fuerst F, Olas J, Paul S, Rotondo C, Rubio-Rivas M, Seferian A, Tomčík M, Uzunhan Y, Walker UA, Więsik-Szewczyk E, Distler O (2020) Evidence-based European consensus statements for the identification and management of interstitial lung disease in systemic sclerosis. Lancet Rheumatology 2:e71–e83

    Google Scholar 

  • Hwang JH, Misumi S, Sahin H et al (2009) Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease. J Comput Assist Tomogr 33:410–415

    Article  PubMed  Google Scholar 

  • Hyldgaard C, Hilberg O, Muller A, Bendstrup E (2014) A cohort study of interstitial lung diseases in central Denmark. Respir Med 108(5):793–799

    Article  PubMed  Google Scholar 

  • Hyldgaard C et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76:1700–1706

    Article  PubMed  Google Scholar 

  • Jagirdar J, Chikkamuniyappa S, Sirohi D (2013) Cystic lung lesions in Sjogrens syndrome: analysis of lymphocyte subsets in tissue with clinico-radiologic-pathologic correlation. Ann Diagn Pathol 17:113–116

    Article  PubMed  Google Scholar 

  • Juge P-A et al (2020) Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J 2000337

    Google Scholar 

  • Kalluri M, Oddis CV (2010) Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med 31:501–512

    Article  PubMed  Google Scholar 

  • Keir G, Maher TM, Ming D et al (2014) Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19:353–359

    Article  PubMed  Google Scholar 

  • Khanna D, Denton CP, Lin CJF et al (2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 77:212–220. https://doi.org/10.1136/annrheumdis-2017-211682

    Article  CAS  PubMed  Google Scholar 

  • Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8(10):963–974. https://doi.org/10.1016/S2213-2600(20)30318-0

    Article  CAS  PubMed  Google Scholar 

  • Koreeda Y, Higashimoto I, Yamamoto M et al (2010) Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoanibodies. Intern Med 4:361–369

    Article  Google Scholar 

  • Kowal-Bielecka O, Landewe R, Avouac J et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUSTAR). Ann Rheum Dis 68:620–628

    Article  CAS  PubMed  Google Scholar 

  • Kowal-Bielecka O et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327–1339

    Article  PubMed  Google Scholar 

  • Kreider M, Highland K (2014) Pulmonary involvement in Sjögren syndrome. Semin Respir Crit Care Med 35:255–264

    Article  PubMed  Google Scholar 

  • van Laar JM, Farge D, Sont JK et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490–2498. (EBMT/EULAR Scleroderma Study Group)

    Article  PubMed  CAS  Google Scholar 

  • Le Pavec J, Girgis RE, Lechtzin N et al (2011) Systemic sclerosisrelated pulmonary hypertension associated with interstitiallung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 63:2456–2464

    Article  PubMed  Google Scholar 

  • Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V (2020) Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 8(2):147–157

    Article  CAS  PubMed  Google Scholar 

  • Mathai SC, Danoff SK (2016) Management of interstitial lung disease associated with connective tissue disease. BMJ 352:h6819

    Article  PubMed  PubMed Central  Google Scholar 

  • Nannini C, Jebakumar AJ, Crowson CS (2013) Primary Sjogren’s syndrome 1976–2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 3(11):e003569

    Article  PubMed  PubMed Central  Google Scholar 

  • Nikpour M, Baron M (2014) Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol 26:131–137

    Article  PubMed  Google Scholar 

  • Park JH, Kim DS, Park IN et al (2007) Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175:705–711

    Article  PubMed  Google Scholar 

  • Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C et al (2011) Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 41:256–264

    Article  CAS  PubMed  Google Scholar 

  • Prasse A, Costabel U (2008) Lungenbeteiligung bei Systemerkrankungen. In: Matthys H, Seeger W (Hrsg) Klinische Pneumologie, 4. Aufl. Springer, Heidelberg

    Google Scholar 

  • Rojas Serrano J et al (2017) Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol 36:1493–1500

    Article  PubMed  Google Scholar 

  • Romagnoli M, Nannini C, Piciucchi S et al (2011) Idiopathic nonspecific interstitial pneumonia. An interstitial lung disease associated with autoimmune disorders? Eur Respir J 38:384–391

    Article  CAS  PubMed  Google Scholar 

  • Schotte H, Becker H, Domschke W, Gaubitz M (2005) Kardiovaskuläres Monitoring von Patienten mit systemischem Lupus erythematodes. Z Rheumatol 64(8):564–575

    Article  CAS  PubMed  Google Scholar 

  • Solomon JJ, Olson AL, Fischer A (2013) Scleroderma lung disease. Eur Respir Rev 22(127):6–19

    Article  PubMed  PubMed Central  Google Scholar 

  • Solomon JJ, Chartrand S, Fischer A (2014) Current approach to connective tissue disease-associated interstitial lung disease. Curr Opin Pulm Med 20:449–456

    Article  PubMed  Google Scholar 

  • Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE, SCOT Study Investigators (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 378(1):35–47

    Article  PubMed  PubMed Central  Google Scholar 

  • Tahskin DP, Elashoff R, Clements PF et al (2006) Cyclophosphamide versus placebo scleroderma lung disease. N Engl J Med 354:2655–2666

    Article  Google Scholar 

  • Tahskin DP, Elashoff R, Clements PJ et al (2007) Effects of 1-year treatment with cyclophosphamide on outcoes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176:1026–1034

    Article  CAS  Google Scholar 

  • Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, GHJ K, Tseng CH, Elashoff RM, Sclerodema Lung Study II Investigators (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tyndal AJ, Baner B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809–1815

    Article  Google Scholar 

  • Valeyre D, Duchemann B, Nunes H, Uzunhan Y, Annesi-Maesanoin I (2014) Interstitial lung diseases. In: Welte T (Hrsg) ERS monograph, respiratory epidemiology. European Respiratory Society, UK, S 79–87

    Google Scholar 

  • Vij E, Strek ME (2013) Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 143:814–824

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Walker WC, Wright V (1968) Pulmonary lesions and rheumatoid arthritis. Medicine 47:501–520

    Article  CAS  PubMed  Google Scholar 

  • Winstone TA, Assayag D, Wilcox PG et al (2014) Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 146:422–436

    Article  PubMed  Google Scholar 

  • Yang X, Mardekian J, Sanders KN, Mychaskiw MA, Thomas J 3rd (2013) Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol 32(10):1519–1531

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum für interstitielle und seltene Lungenerkrankungen, Thoraxklinik, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    Michael Kreuter

  2. Deutsches Zentrum für Lungenforschung, Heidelberg, Deutschland

    Michael Kreuter

  3. Medizinische Klinik und Poliklinik V, Sektion Rheumatologie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    Hanns-Martin Lorenz

  4. Ruhrlandklinik, Zentrum für interstitielle und seltene Lungenerkrankungen, Klinik für Pneumologie, Universitätsmedizin Essen, Essen, Deutschland

    Francesco Bonella

  5. Lungenpraxis Leonberg, Leonberg, Deutschland

    Martin Kohlhäufl

  6. Abteilung für Rheumatologie, Universitätsklinikum, Oslo, Norwegen

    Anna-Maria Hoffmann-Vold

Authors
  1. Michael Kreuter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanns-Martin Lorenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Bonella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Kohlhäufl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna-Maria Hoffmann-Vold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Kreuter .

Editor information

Editors and Affiliations

  1. Zentrum für interstitielle und seltene Lungenerkrankungen, Thoraxklinik, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    Michael Kreuter

  2. Ruhrlandklinik, Universitätsmedizin Essen, Essen, Deutschland

    Ulrich Costabel

  3. Thoraxklinik, Pneumologie und Beatmungsmedizin und Translational Lung Research Center (TLRCH), Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    Felix JF Herth

  4. Vormals LungenClinic Grosshansdorf, Grosshansdorf, Deutschland

    Detlef Kirsten

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kreuter, M., Lorenz, HM., Bonella, F., Kohlhäufl, M., Hoffmann-Vold, AM. (2022). Pulmonale Manifestationen rheumatologischer Erkrankungen. In: Kreuter, M., Costabel, U., Herth, F.J., Kirsten, D. (eds) Seltene Lungenerkrankungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-63651-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-63651-0_8

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-63650-3

  • Online ISBN: 978-3-662-63651-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation